Education
About Us
Working with TipRanks
Follow Us
BeiGene (ONC)
NASDAQ:ONC
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.46Last Year’s EPS
-2.41Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -4.61%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and market leadership for BRUKINSA, along with robust R&D productivity. However, challenges remain in the competitive landscape and in achieving desired outcomes with fixed duration treatments. Overall, the positives significantly outweigh the negatives.Company Guidance
In BeiGene's Q4 and Full Year 2024 earnings call, the company provided strong financial and strategic guidance for 2025, projecting revenue between $4.9 billion to $5.3 billion, driven by continued global expansion and leadership in the BTK inhibitor market with BRUKINSA. The U.S. remains a significant market, contributing to the $3.8 billion total revenue in 2024, with BRUKINSA alone generating $828 million in Q4, marking a 100% year-over-year growth. For 2025, BeiGene expects stable net pricing in the U.S. and anticipates robust performance in Europe and rest of world markets, including Japan. The company aims to achieve full-year GAAP operating breakeven and positive cash flow from operations, emphasizing a disciplined investment approach to maintain a strong balance sheet while advancing their innovative pipeline. Key strategic focuses include solidifying leadership in the hematology franchise, advancing the pipeline of internally developed assets, and driving superior financial performance.Record Revenue and Growth
BeiGene achieved $3.8 billion in revenue for the full year 2024, with $1.1 billion in Q4. This represented a 55% year-over-year revenue growth, with product revenues increasing by 73%.
BRUKINSA's Market Leadership
BRUKINSA became the BTKi class leader for new patient starts in the U.S., achieving $828 million in sales in Q4, representing a 100% growth compared to Q4 2023.
Strong Financial Guidance for 2025
BeiGene projected revenue for 2025 to be between $4.9 billion to $5.3 billion, with an expectation of full year GAAP operating breakeven and positive cash flow from operations.
R&D Productivity
Introduced 13 new molecular entities into the clinic in 2024, demonstrating strong R&D productivity and pipeline progress.
---
ONC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ONC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $259.00 | $278.38 | +7.48% |
| Nov 12, 2024 | $205.04 | $193.64 | -5.56% |
| Aug 27, 2024 | $199.22 | $202.17 | +1.48% |
| May 08, 2024 | $160.56 | $164.44 | +2.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BeiGene (ONC) report earnings?
BeiGene (ONC) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is BeiGene (ONC) earnings time?
BeiGene (ONC) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ONC EPS forecast?
ONC EPS forecast for the fiscal quarter 2025 (Q1) is -0.46.
---